aTyr Pharma, Inc. (Nasdaq: ATYR) announced it will present a subgroup analysis of its Phase 3 EFZO-FIT™ study of efzofitimod ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE